References
- Mitani K. Molecular mechanisms of leukemogenesis by AML1/EVI1. Oncogene 2004; 23: 4263–4269
- Jolkowska J, Witt M. The EVI-1 gene – its role in pathogenesis of human leukemias. Leuk Res 2000; 24: 553–558
- Morishita K, Parganas E, William C L, Whittaker M H, Drabkin H, Oval J, et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300 – 400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937–3941
- Russell M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994; 84: 1243–1248
- Barjesteh van Waalwijk, van Doorn-Khosrovani S, Erpelinck C, van Putten W L, Valk P J, van der Poel-van de Luytgaarde S, et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837–845
- Langabeer S E, Rogers J R, Harrison G, Wheatley K, Walker H, Bain B J, et al. EVI1 expression in acute myeloid leukaemia. Br J Haematol 2001; 112: 208–211
- Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon 2001
- ISCN 1995. Guidelines for cancer cytogenetics. Supplement to an international system for human cytogenetic nomenclature, F Mitelman. S. Karger, Basel 1995
- Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825–1832
- Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755
- Buonamici S, Ottaviani E, Testoni N, Montefusco V, Visani G, Bonifazi F, et al. Real-time quantitation of minimal residual disease in inv (16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002; 99: 443–449
- Marcucci G, Caligiuri M A, Dohner H, Archer K J, Schlenk R F, Dohner K. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080
- Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, Schnittger S. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416–1423
- Garg M, Moore H, Tobal K, Liu Yin J A. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003; 123: 49–59